Biopharmaceutical benchmarks: Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline

Nature Biotechnology

Volumn 18, Issue 8, 2000, Pages 831-833

  Walsh, G ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; INSULIN; PACLITAXEL; RECOMBINANT GROWTH HORMONE; RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DRUG INDUSTRY; ENZYME THERAPY; GENE SEQUENCE; GENE THERAPY; HUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; DRUG APPROVAL; ECONOMICS; ORGANIZATION AND MANAGEMENT;

BIOTECHNOLOGY; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; RECOMBINANT PROTEINS;

EID: 0034241572     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/78720     Document Type: Review

References (11)

1. Transgenic protein production; the technology and major players
2. Transgenic protein production: Process economics
3. Dolly, Polly and other 'ollys': Likely impact of cloning technology on biomedical uses of livestock
4. Functional genomics: From genes to new therapies
5. Knowledge based discovery in gene expression microarray data; mining the information output of the genome
6. Proteomics in drug discovery
7. Proteomics: Quantitative and physical mapping of cellular proteins